Zevalin™ (ibritumomab tiuxetan): Proposed Indication
Treatment of patients with relapsed or refractory, low-grade, follicular, or CD20+ transformed B-cell non-Hodgkin’s lymphoma (NHL) and treatment of patients with rituximab-refractory follicular NHL